Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity

Objective The uptake carrier organic anion-transporting polypeptide 1B3 (OATP1B3, gene SLCO1B3) is involved in the hepatic clearance of xenobiotics including statins, taxanes, and mycophenolic acid. We thought to assess the SLCO1B3 coding region for yet unidentified polymorphisms and to analyze their functional relevance. Methods We used DNA of ethnically diverse individuals for polymerase chain reaction, and determined polymorphisms by sequencing or temperature-dependent capillary electrophoresis. We then created variant OATP1B3 expression plasmids by site-directed mutagenesis, which were transiently expressed and functionally characterized in human cervical carcinoma (HeLa) cells using radiolabeled substrates. Results We identified six nonsynonymous polymorphisms including novel variants such as 439A>G (Thr147Ala), 767G>C (Gly256Ala), 1559A>C (His520Pro), and 1679T>C (Val560Ala). Allelic frequencies occurred to be ethnicity-dependent, with the latter observed only in African–Americans (3.6%). After expression in HeLa cells, His520Pro, Val560Ala, and Met233Ile or Met233Ile_Ser112Ala haplotype variants showed decreased uptake activity compared with wild type for cholecystokinin-8 and rosuvastatin, but not for atorvastatin. Kinetic cholecystokinin-8 analysis showed reduced Vmax without altering Km. His520Pro and Val560Ala exhibited decreased total and plasma membrane protein expressions. Val560 mapped onto a structural model of OATP1B3 showed that this is a key region for substrate–transporter interaction. His520 resides in a predicted extracellular region thought to be critical to the pH-dependent component of OATP1B3 activity. Loss of activity at pH 7.4 and 8.0 relative to pH 6.5 was significantly greater for the Pro520 variant. Conclusion OATP1B3 polymorphisms that result in altered expression, substrate specificity, and pH-dependent activity may be of potential relevance to hepatic clearance of substrate drugs in vivo.

[1]  Bradley L Urquhart,et al.  Human Skeletal Muscle Drug Transporters Determine Local Exposure and Toxicity of Statins , 2010, Circulation research.

[2]  K. Giacomini,et al.  The Role of Organic Anion–Transporting Polypeptides and Their Common Genetic Variants in Mycophenolic Acid Pharmacokinetics , 2010, Clinical pharmacology and therapeutics.

[3]  Bruno Stieger,et al.  Mechanisms of pH-gradient driven transport mediated by organic anion polypeptide transporters. , 2009, American journal of physiology. Cell physiology.

[4]  A. Wolff,et al.  Pharmacogenetic Pathway Analysis of Docetaxel Elimination , 2009, Clinical pharmacology and therapeutics.

[5]  M. Washington,et al.  Overexpression of OATP1B3 confers apoptotic resistance in colon cancer. , 2008, Cancer research.

[6]  A. Sparreboom,et al.  Influence of Solute Carriers on the Pharmacokinetics of CYP3A4 Probes , 2008, Clinical pharmacology and therapeutics.

[7]  T. Habuchi,et al.  Influence of Drug Transporters and UGT Polymorphisms on Pharmacokinetics of Phenolic glucuronide Metabolite of Mycophenolic Acid in Japanese Renal Transplant Recipients , 2008, Therapeutic drug monitoring.

[8]  C. Gui,et al.  Amino acid residues in transmembrane domain 10 of organic anion transporting polypeptide 1B3 are critical for cholecystokinin octapeptide transport. , 2008, Biochemistry.

[9]  D. Venzon,et al.  Effect of SLCO1B3 Haplotype on Testosterone Transport and Clinical Outcome in Caucasian Patients with Androgen-Independent Prostatic Cancer , 2008, Clinical Cancer Research.

[10]  P. Neuvonen,et al.  Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin , 2007, Clinical pharmacology and therapeutics.

[11]  T. Habuchi,et al.  Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients , 2007, European Journal of Clinical Pharmacology.

[12]  R. Kim,et al.  Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants , 2007, Pharmacogenetics and genomics.

[13]  H. McLeod,et al.  Variants in the SLCO1B3 Gene: Interethnic Distribution and Association with Paclitaxel Pharmacokinetics , 2007, Clinical pharmacology and therapeutics.

[14]  P. Meier,et al.  Functional Analysis of the Extracellular Cysteine Residues in the Human Organic Anion Transporting Polypeptide, OATP2B1 , 2006, Molecular Pharmacology.

[15]  Kazuya Maeda,et al.  PREDOMINANT CONTRIBUTION OF OATP1B3 TO THE HEPATIC UPTAKE OF TELMISARTAN, AN ANGIOTENSIN II RECEPTOR ANTAGONIST, IN HUMANS , 2006, Drug Metabolism and Disposition.

[16]  T. Abe,et al.  OATP1B1, OATP1B3, AND MRP2 ARE INVOLVED IN HEPATOBILIARY TRANSPORT OF OLMESARTAN, A NOVEL ANGIOTENSIN II BLOCKER , 2006, Drug Metabolism and Disposition.

[17]  R. Kim,et al.  Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. , 2006, Gastroenterology.

[18]  K. Mizuguchi,et al.  Organic Anion Transporting Polypeptides of the OATP/SLCO Superfamily: Identification of New Members in Nonmammalian Species, Comparative Modeling and a Potential Transport Mode , 2006, The Journal of Membrane Biology.

[19]  M. Fromm,et al.  Pharmacogenomics of human OATP transporters , 2006, Naunyn-Schmiedeberg's Archives of Pharmacology.

[20]  A. Sparreboom,et al.  Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel , 2005, Cancer biology & therapy.

[21]  Nashville Tennessee,et al.  Polymorphisms in Human Organic Anion-transporting Polypeptide 1A2 (OATP1A2) , 2005, Journal of Biological Chemistry.

[22]  R. Kim,et al.  Pharmacogenomics of the OATP and OAT families. , 2004, Pharmacogenomics.

[23]  D. Keppler,et al.  Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8). , 2004, Pharmacogenetics.

[24]  R. Kim,et al.  Organic anion‐transporting polypeptide (OATP) transporter family and drug disposition , 2003, European journal of clinical investigation.

[25]  P. Meier,et al.  The superfamily of organic anion transporting polypeptides. , 2003, Biochimica et biophysica acta.

[26]  P. Meier,et al.  Hepatic uptake of cholecystokinin octapeptide by organic anion-transporting polypeptides OATP4 and OATP8 of rat and human liver , 2001 .

[27]  T. Abe,et al.  LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. , 2001, Gastroenterology.

[28]  P. Meier,et al.  Hepatic uptake of cholecystokinin octapeptide by organic anion-transporting polypeptides OATP4 and OATP8 of rat and human liver. , 2001, Gastroenterology.

[29]  D. Keppler,et al.  Localization and Genomic Organization of a New Hepatocellular Organic Anion Transporting Polypeptide* , 2000, The Journal of Biological Chemistry.

[30]  Mark M. Roden,et al.  Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activity. , 1999, The Journal of pharmacology and experimental therapeutics.

[31]  Abstr Act,et al.  SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study , 2008 .

[32]  Y. Sawada,et al.  Polymorphisms and linkage disequilibrium of the OATP8 (OATP1B3) gene in Japanese subjects. , 2006, Drug metabolism and pharmacokinetics.